Cargando…

USP26 regulates TGF‐β signaling by deubiquitinating and stabilizing SMAD7

The amplitude of transforming growth factor‐β (TGF‐β) signal is tightly regulated to ensure appropriate physiological responses. As part of negative feedback loop SMAD7, a direct transcriptional target of downstream TGF‐β signaling acts as a scaffold to recruit the E3 ligase SMURF2 to target the TGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Kit Leng Lui, Sarah, Iyengar, Prasanna Vasudevan, Jaynes, Patrick, Isa, Zul Fazreen Bin Adam, Pang, Brendan, Tan, Tuan Zea, Eichhorn, Pieter Johan Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412796/
https://www.ncbi.nlm.nih.gov/pubmed/28381482
http://dx.doi.org/10.15252/embr.201643270
Descripción
Sumario:The amplitude of transforming growth factor‐β (TGF‐β) signal is tightly regulated to ensure appropriate physiological responses. As part of negative feedback loop SMAD7, a direct transcriptional target of downstream TGF‐β signaling acts as a scaffold to recruit the E3 ligase SMURF2 to target the TGF‐β receptor complex for ubiquitin‐mediated degradation. Here, we identify the deubiquitinating enzyme USP26 as a novel integral component of this negative feedback loop. We demonstrate that TGF‐β rapidly enhances the expression of USP26 and reinforces SMAD7 stability by limiting the ubiquitin‐mediated turnover of SMAD7. Conversely, knockdown of USP26 rapidly degrades SMAD7 resulting in TGF‐β receptor stabilization and enhanced levels of p‐SMAD2. Clinically, loss of USP26 correlates with high TGF‐β activity and confers poor prognosis in glioblastoma. Our data identify USP26 as a novel negative regulator of the TGF‐β pathway and suggest that loss of USP26 expression may be an important factor in glioblastoma pathogenesis.